

# STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-179) PEGTIBATINASE

PRONUNCIATION peg" tye ba' tin ase

THERAPEUTIC CLAIM Treatment of homocystinuria

## CHEMICAL NAMES

1. 2-413-Cystathionine  $\beta$ -synthase [15-serine] (recombinant human clone OT-58), pegylated (Source: CAS)
2. human cystathionine  $\beta$ -synthase fragment (2-413, M<sup>1</sup> cleaved) mutant (C<sup>15</sup>>S), homodimer, produced in *Escherichia coli*, pegylated at N<sup>6</sup> of lysine residues with an average of five 5-[ $\alpha$ -methylpoly(oxyethylene)- $\omega$ -oxy]-5-oxopentanoyl groups per protein monomer; des-Met1-[Cys<sup>15</sup>>Ser] human cystathionine  $\beta$ -synthase (CBS, betathionase, serine sulfhydrase, EC:4.2.1.22) (2-413)-peptide, non-covalent dimer, produced in *Escherichia coli*, substituted with approximately five 5-[ $\alpha$ -methylpoly(oxyethylene)- $\omega$ -oxy]-5-oxopentanoyl groups (20 kDa each) per protein monomer at N<sup>6</sup> of lysine residues (Source: WHO pINN list 123)

## STRUCTURAL FORMULA

### Sequence

PSETPQAEV	GPTGSPHRSG	PHSAKGSLEK	GSPEDKEAKE	PLWIRPDAPS	50
RCTWQLGRPA	SESPHHHTAP	AKSPKILPDI	LKKIGDTPMV	RINKIGKKFG	100
LKCELLAKCE	FFNAGGSVKD	RISLRMIEDA	ERDGTKPGD	TIIPTSGNT	150
GIGLALAAAV	RGYRCIIVMP	EKMSSEKVDV	LRALGAEIVR	TPTNARFDSP	200
ESHVGVAVRL	KNEIPNSHIL	DQYRNASNPL	AHYDTTAEI	LQQCDGKLDM	250
LVASVGTGGT	ITGIARKLKE	KCPGCRIIGV	DPEGSILAEP	EELNQTEQTT	300
YEVEGIGYDF	IPTVLDRTVV	DKWFKSNDEE	AFTFARMLIA	QEGLLCGGSA	350
GSTVAVAVKA	AQELQEGQRC	VVILPDSVRN	YMTKFLSDRW	MLQKGFLKEE	400
DLTEKKPWWW	HLR				415


### Disulfide bridges

272'-275'      272'-275'

### Glycosylation sites (N)

none

### Pegylation



~5 K per monomer =

MOLECULAR FORMULA Not determined

MOLECULAR WEIGHT Not determined

TRADEMARK	None as yet
SPONSOR	Traverse Therapeutics Inc.
CODE DESIGNATIONS	TVT-058, OT-58
<u>CAS</u> REGISTRY NUMBER	2304692-47-3
UNII	3G3529LUQ7
WHO NUMBER	11414

gbk